Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2

We examined whether commercial prepandemic intravenous immunoglobulin (IVIG) contains cross-reactive antibodies that could bind and neutralize SARS-CoV-2. The receptor-binding domain (RBD), contained within the S1 subunit of the coronavirus spike protein, mediates viral entry by binding to the angiotensin-converting enzyme 2 receptor on host cells.

Source: Journal of Allergy and Clinical Immunology - December 17, 2020 Category: Allergy & Immunology Authors: Terrie S. Ahn, Brandon Han, Paul Krogstad, Chantana Bun, Lisa A. Kohn, Maria I. Garcia-Lloret, Robert Damoiseaux, Manish J. Butte Tags: Correspondence Source Type: research